Meropenem Aurovitas (Meropenem Trihydrate)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which blocks the final cross‑linking step of peptidoglycan formation. This leads to weakened cell walls, osmotic instability and bacterial lysis. Its structure resists most β‑lactamases, giving it activity against many resistant organisms.

The prescribed dose of Meropenem Aurovitas is set by the treating physician based on the type and severity of infection, the patient’s renal function, age, weight and any concomitant medications. Dosing regimens are individualized and should follow local clinical guidelines.

The pregnancy category for Meropenem is listed as unknown. It should be used during pregnancy or lactation only when the potential therapeutic benefit justifies any possible risk to the fetus or infant. Clinicians must weigh the infection severity against limited safety data.

To place an order, submit an enquiry on the Meropenem Aurovitas product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Meropenem shares the broad‑spectrum activity typical of carbapenems but offers a slightly lower risk of neurotoxicity compared with imipenem and a more convenient dosing interval than ertapenem for certain infections. Its stability against many β‑lactamases makes it a preferred option for multidrug‑resistant Gram‑negative organisms.

Meropenem Aurovitas should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The powder must be reconstituted with the appropriate diluent immediately before use, and the solution should be administered within the time frame recommended in the product label.

The product is supplied as a sterile powder for intravenous infusion. After reconstitution with a compatible diluent, the solution is infused over a prescribed period, typically 15‑30 minutes, using aseptic technique. Administration is performed by qualified healthcare professionals in a clinical setting.

Serious adverse events include seizures (especially in patients with renal impairment or pre‑existing CNS disorders), severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and discontinuation of therapy are essential if any of these occur.

Meropenem Aurovitas is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of severe allergic reactions, uncontrolled epilepsy, or significant renal dysfunction without appropriate dose adjustment.